Medigene AG: Medigene AG reports nine months' results 2017
Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the dev…
Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the dev…
Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announces that a scientific article on a method to identify T cell…
Maruho to receive exclusive worldwide license on 4SC's preclinical inhibitors of the Kv1.3 ion channel 4SC eligible for…
Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near Munich, Germany, to…
4SC AG (4SC, FSE Prime Standard: VSC) has entered into a licensing and development partnership for the cancer compound 4…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs mainly foc…
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various do…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: VSC) today decided to hold an Extraordinary General Meeting on 11 March 2015. The pri…